ArticleBlood advances2018
Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.Blood advances · 2019Guideline
- Venous Thromboembolism in Neonates, Children, and Adolescents: A Comprehensive Narrative Review of Risk Factors, Diagnosis, Treatment, and Prevention.Medicina (Kaunas, Lithuania) · 2026Review
- Acute Chest Syndrome in Children with Sickle Cell Disease: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Risk factors for venous thromboembolism in sickle cell disease.Research and practice in thrombosis and haemostasis · 2026Article
- Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease.Annals of intensive care · 2025Review
- Proportion and risk factors for hospital-acquired venous thromboembolism in children: a systematic review and meta-analysis of data from 20 million individuals in 22 countries.Research and practice in thrombosis and haemostasis · 2024Article
- A Comparative Analysis of Hydroxyurea Treatment on Coagulation Profile Among Sickle Cell Anaemia Children in Lagos, Nigeria.Advances in hematology · 2024Article
- Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.American journal of hematology · 2023Article
- Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients.Blood advances · 2023Article
- The Role of Inflammation in The Cellular and Molecular Mechanisms of Cardiopulmonary Complications of Sickle Cell Disease.Biomolecules · 2023Review
- Sex as an Independent Risk Factor for Venous Thromboembolism in Sickle Cell Disease: A Cross-Sectional Study.Journal of women's health (2002) · 2022Article
- Predicting risk factors for thromboembolic complications in patients with sickle cell anaemia - lessons learned for prophylaxis.The Journal of international medical research · 2021Article
- How we approach thrombosis risk in children with COVID-19 infection and MIS-C.Pediatric blood & cancer · 2021Article
- The molecular basis for the prothrombotic state in sickle cell disease.Haematologica · 2020Article
- Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.Blood advances · 2020Article
- Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals.Mediterranean journal of hematology and infectious diseases · 2020Review
- High incidence of venous thromboembolism recurrence in patients with sickle cell disease.American journal of hematology · 2019Article
- Gender-Related Differences in Sickle Cell Disease in a Pediatric Cohort: A Single-Center Retrospective Study.Frontiers in molecular biosciences · 2019Article
- Vascular Instability and Neurological Morbidity in Sickle Cell Disease: An Integrative Framework.Frontiers in neurology · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
A hypercoagulable state resulting in increased venous thromboembolism (VTE) has been described in adults with sickle cell disease (SCD), but similar data for children are lacking. The objective of this retrospective cohort study was to describe the rate of VTE and risk factors associated with VTE in children with SCD across tertiary-care children's hospitals in the United States between the years 2009 and 2015. We used the Pediatric Health Information System database to investigate all pediatric patients with SCD admitted to 1 of 48 participating institutions between 1 January 2009 and 30 September 2015. International Classification of Disease, Ninth Edition, Clinical Modification codes were used to identify index thromboembolic events and chronic medical conditions known to be associated with VTE. Billing codes were used to identify central venous line (CVL) placement and pharmaceutical billing codes to identify estrogen containing oral-contraceptive use. Logistic regression analysis was used to study the association among unique patient characteristics, VTE, and death. 10 454 eligible subjects with SCD were identified. Median age (±interquartile range) of study cohort was 10 (±11) years. 181 subjects (1.7%) developed an index venous thromboembolic event during the study period. Median age at VTE diagnosis was 15.9 (±7.4) years. On multivariable logistic regression analysis, CVL placement, chronic renal disease, history of stroke, female sex, length of hospitalization, intensive care unit utilization, and older age were associated with VTE. After adjusting for other variables, VTE was independently associated with death. In summary, VTE can occur in pediatric patients with SCD. CVL placement is a modifiable risk factor for VTE development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.